D
Daniel Aletaha
Researcher at Medical University of Vienna
Publications - 398
Citations - 51111
Daniel Aletaha is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 74, co-authored 298 publications receiving 43215 citations. Previous affiliations of Daniel Aletaha include National Institutes of Health & University of Vienna.
Papers
More filters
Journal ArticleDOI
Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.
Josef S Smolen,Daniel Aletaha,David Gruben,Samuel H. Zwillich,Sriram Krishnaswami,Charles A Mebus +5 more
TL;DR: In this article, tofacitinib is an oral JAK inhibitor that is used for the treatment of rheumatoid arthritis (RA) using a Disease Activity Score in 28 joints (DAS28)-based analysis was used to assess outcomes.
Journal ArticleDOI
Diagnostic and prognostic value of antibodies and soluble biomarkers in undifferentiated peripheral inflammatory arthritis: a systematic review.
TL;DR: Unanimous evidence of substantial diagnostic value exists only for anti-CCP and RF, but is scarce for other markers, including antikeratin antibodies (AKA) and antiperinuclear factor.
Journal ArticleDOI
Challenges of predicting treatment response in patients with rheumatoid arthritis.
Josef S Smolen,Daniel Aletaha +1 more
TL;DR: Current progress in the field of outcomes research in rheumatoid arthritis, along with future prospects of predicting individual patient response to therapy, are considered.
Journal ArticleDOI
Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases.
Nicole Harrison,Wolfgang Poeppl,Manuel Miksch,Klaus P Machold,Hans P. Kiener,Daniel Aletaha,Josef S Smolen,Christina Forstner,Heinz Burgmann,Heimo Lagler +9 more
TL;DR: A moderate influenza vaccination rate of 25.3% was detected among patients with inflammatory rheumatic diseases and recommendation of the influenza vaccine by a physician exerts the most effective impact on a positive vaccination status.
Posted ContentDOI
Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity
Thomas Perkmann,Nicole Perkmann-Nagele,Marie-Kathrin Breyer,Robab Breyer-Kohansal,Otto C. Burghuber,Sylvia Hartl,Daniel Aletaha,Daniela Sieghart,Peter Quehenberger,Rodrig Marculescu,Patrick Mucher,Robert Strassl,Oswald Wagner,Christoph J. Binder,Helmuth Haslacher +14 more
TL;DR: Differences in specificities for the anti-SARS-CoV-2 antibody assays by Abbott, Roche, and DiaSorin that have a significant impact on the positive predictability of these tests are found.